Publicaciones en las que colabora con Juan Carlos Ruiz San Millán (18)

2023

  1. Lymphoproliferative disorders after renal transplantation along 2 decades: A large longitudinal study of 21,546 recipients

    Nefrologia, Vol. 43, Núm. 4, pp. 427-434

  2. Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients

    Nefrologia, Vol. 43, Núm. 4, pp. 427-434

  3. Post-transplant diabetes mellitus and renal cell cancer after renal transplantation

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, Núm. 6, pp. 1552-1559

  4. Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients

    Nefrologia, Vol. 43, Núm. 5, pp. 531-545

2022

  1. Live donor kidney transplantation. Situation analysis and roadmap

    Nefrologia, Vol. 42, Núm. 1, pp. 85-93

  2. Urinary CXCL10 specifically relates to HLA-DQ eplet mismatch load in kidney transplant recipients

    Transplant Immunology, Vol. 70

2020

  1. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients

    Nefrologia, Vol. 40, Núm. 3, pp. 265-271

  2. Use of tocilizumab in kidney transplant recipients with COVID-19

    American Journal of Transplantation, Vol. 20, Núm. 11, pp. 3182-3190

2019

  1. Direct-Acting Antivirals for the Treatment of Kidney Transplant Patients with Chronic Hepatitis C Virus Infection in Spain: A Long-Term Prospective Observational Study

    Transplantation Direct, Vol. 5, Núm. 12

  2. Early outcomes of kidney transplantation from elderly donors after circulatory death (GEODAS study)

    BMC Nephrology, Vol. 20, Núm. 1

2017

  1. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus

    Transplant International, Vol. 30, Núm. 1, pp. 83-95

2015

  1. Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted from Twice-Daily to Once-Daily Tacrolimus

    Transplantation Direct, Vol. 1, Núm. 7, pp. E24

2012

  1. Management of proteinuria in clinical practice after kidney transplantation

    Transplantation Reviews, Vol. 26, Núm. 1, pp. 36-43

  2. Prediction of kidney transplant outcome by donor quality scoring systems: Expanded criteria donor and deceased donor score

    Transplantation Proceedings

2011

  1. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients

    American Journal of Transplantation, Vol. 11, Núm. 9, pp. 1965-1971

  2. Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?

    Transplantation Proceedings, Vol. 43, Núm. 6, pp. 2194-2195

2010

  1. Influence of interleukin-6 promoter polymorphism -174 G/C on kidney graft outcome

    Transplantation Proceedings, Vol. 42, Núm. 8, pp. 2854-2855

2007

  1. Use of the New Proliferation Signal Inhibitor Everolimus in Renal Transplant Patients in Spain: Preliminary Results of the EVERODATA Registry

    Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2157-2159